Our most read stories of 2015
As 2015 is beginning to wrap up European Pharmaceutical Manufacturer has looked at our most popular stories
CPhI disrupted by “major superbug outbreak”
In October this year environmental activists infiltrating CPhI was of great interest to EPM’s readers. The activists infiltrated the event “in protest against the industry’s role in the global rise of antibiotic-resistant bacteria”.
To read this article click here.
Making feasibility more reliable in clinical trials
Clinical trial complexity is placing a greater emphasis on, and creating a critical need for, study feasibility. In this article PAREXEL discussed the key factors for achieving more reliable feasibility in clinical trials.
To read this article by guest authors Muriel Berthier and Denis McMillan click here.
FDA has accepted the first digital medicine product
Back in September Aripiprazole was combined with an ingestible sensor to create a combination product, Abilify, which achieved New Drug Application (NDA) acceptance from the Food and Drug Administration (FDA).
To read this article click here.
Strategic thinking: How pharma can benefit from a digital marketing strategy
In 2015 many pharmaceutical firms still remain concerned about managing or creating social and digital marketing activities. In this article Hallam Internet, offered advice on how to redefine pharmaceutical digital marketing strategies.
To read this article by guest authors Nada Giuffrida and Kym Ellis click here.
Why high potency drugs require a specialised approach
Highly potent active pharmaceutical ingredients (HPAPIs), including both small molecules and biologics, continue to increase as a share of the drug development pipeline facilitated by high throughput screening. In this article Encap Drug Delivery described why the safe manufacturing of high potency drugs requires a specialised approach.
To read this article by guest author Stephen Brown click here.